GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Accumulated Depreciation

ME Therapeutics Holding (XCNQ:METX) Accumulated Depreciation : C$0.00 Mil (As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.


ME Therapeutics Holding Accumulated Depreciation Historical Data

The historical data trend for ME Therapeutics Holding's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Accumulated Depreciation Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Accumulated Depreciation
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Accumulated Depreciation Get a 7-Day Free Trial - - - - -

ME Therapeutics Holding Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.


ME Therapeutics Holding Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.


ME Therapeutics Holding (XCNQ:METX) Business Description

Comparable Companies
Traded in Other Exchanges
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines